Prehab Prior to Stem Cell Transplantation in Multiple Myeloma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Supported Exercise, Standard Care.
- Who it may be relevant to
- Registry conditions: Multiple Myeloma, Exercise, Prehabilitation. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Multiple Myeloma Exercise Prehabilitation for Individuals Awaiting a Stem Cell Transplantation (MOTIVATE): A Randomized Controlled Feasibility Trial
Overview
The primary purpose of this study is to see if individuals with Multiple Myeloma are able and interested in taking part in a tailored exercise program while undergoing their chemotherapy prior to a stem cell transplant. We also hope to learn if this type of program, along with a flexible delivery format (in-person and virtual), helps in maintaining or improving physical fitness, muscle mass and strength, and quality of life during chemotherapy.
Detailed description
MOTIVATE is a multi-methods feasibility randomized trial. We will recruit a minimum of 30 individuals with multiple myeloma who are undergoing chemotherapy prior to a Stem Cell Transplant. The study will be conducted in two phases:
Phase I: Feasibility Study The aim of this phase is to determine the feasibility and preliminary effectiveness of a 10-week exercise intervention compared to physical activity counseling alone.
Phase II: Qualitative Study The aim of this phase is to evaluate the acceptability of the Healthy Eating Active Living (HEAL-ME) app design, program delivery/design, and perceived effectiveness of the intervention at the level of the participant.
Interventions
- Behavioral Supported Exercise
Participants will take part in a prehabilitation exercise program prior to undergoing a stem cell transplant. - Behavioral Standard Care
Participants will receive standard care
Primary outcome measures
- Study completion rate [Time frame: 10-weeks]
Secondary outcome measures (12)
- Recruitment rate [Time frame: 18 months]
- Attendance rate [Time frame: 18 months]
- Edmonton Symptom Assessment System [Time frame: 10 weeks]
- Functional Assessment of Cancer Therapy Multiple Myeloma [Time frame: 10 weeks]
- Functional Assessment of Cancer Therapy: Fatigue Subscale (13-item) [Time frame: 10 weeks]
- Body weight [Time frame: 10 weeks]
- Body height [Time frame: 10 weeks]
- Grip Strength [Time frame: 10 weeks]
- Calf muscle size [Time frame: 10 weeks]
- Thigh muscle thickness [Time frame: 10 weeks]
- Short Physical Performance Battery [Time frame: 10 weeks]
- Six-minute walk test [Time frame: 10 weeks]
Eligibility criteria
Inclusion criteria
- Have a diagnosis of Multiple Myeloma
- Be transplant eligible
- Be undergoing chemotherapy prior to, or following an autologous stem cell transplant as part of their cancer treatment; or transplant ineligible.
- Be an Alberta resident
- Be ≥18 years of age
- Be able to read and understand English.
Exclusion criteria
- Their disease status/comorbidities preclude exercise testing or participation
- They are unable to commit to the 10-week exercise program and/or testing sessions at the Cancer Rehabilitation Clinic at the University of Alberta
- They do not have regular access to the internet and/or an electronic device in the home.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Supportive care
Study locations
Canada · 1 center
- University of Alberta/ Cross Cancer Institute — Edmonton
Identifiers
NCT: NCT06280924 · HREBA.CC-23-0220